Cell Signaling Technology is proud to present the following On-Demand Webinar:
The Use of Highly Validated Antibodies and Optimized ChIP Assays to Analyze Epigenetic Marks and Mechanism in DIsease
Sayura Aoyagi, Ph.D, CST Antibody Validation Scientist
Research in the field of epigenetics has grown at a rapid pace since the discovery of the first histone acetyltransferase enzymes 18 years ago. Since then, significant advances have been made in our understanding of the basic mechanisms of epigenetics (histone acetylation, histone methylation, chromatin remodeling and DNA methylation) and the impact of epigenetic deregulation on cancer, inflammation, metabolism, and neurological diseases. This impact on disease has been underscored by the recent identification of potential oncogenic mutations and losses of epigenetic regulators such as the histone methyltransferase EZH2 and chromatin remodeling protein ARID1A.
The chromatin IP (ChIP) assay is a widely used application and has provided a wealth of information regarding the localization and abundance of epigenetic marks and DNA-binding proteins across the genome in many cell types and tissues. In this webinar, we will present on important factors to consider when performing the ChIP assay, including use of highly validated antibodies, optimized protocols and reagents, and the advantages of using enzyme-based chromatin digestion over sonication-based chromatin fragmentation.
Chromatin Immunoprecipitation | Cell Signaling Technology
